Who is overseeing the improvement plan?

The Board of Directors and Audit & Risk Management Committee are monitoring the implementation to ensure compliance.

What caused the excessive lending?

The exact cause hasn't been disclosed, but it likely stemmed from operational decisions at the U.S. subsidiary.

Can similar issues be prevented in the future?

Yes, with new operational procedures and revised internal controls, recurrence is expected to be minimized.

AI News NQ Analysis

Mei-Shi Announces Implementation Status of Subsidiary's Plan to Rectify Excessive Lending to Third Parties

AI Summary (NQ-processed)

Alvogen Pharma US Inc., a 100% subsidiary of Mei-Shi, has completed its improvement plan regarding excessive fund lending by June 30, 2026, as required by Taiwan's Financial Supervisory Commission. The board of directors has been informed.

AI Analysis

Frequently Asked Questions

Q: Who is overseeing the improvement plan?: A: The Board of Directors and Audit & Risk Management Committee are monitoring the implementation to ensure compliance.
Q: What caused the excessive lending?: A: The exact cause hasn't been disclosed, but it likely stemmed from operational decisions at the U.S. subsidiary.
Q: Can similar issues be prevented in the future?: A: Yes, with new operational procedures and revised internal controls, recurrence is expected to be minimized.